Form 4: Cytokinetics CEO Robert Blum Sells 5,000 Shares Under Pre-Arranged Plan

Cytokinetics Inc.'s President and CEO, Robert I. Blum, sold 5,000 shares of common stock for $33.55 per share on July 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Robert I. Blum, President & CEO and Director of Cytokinetics Inc. (CYTK), reported the sale of 5,000 shares of common stock.
• The transaction occurred on July 1, 2025, at a price of $33.55 per share.
• The sale was executed under a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Mr. Blum directly beneficially owns 398,108 shares of common stock.
• Additionally, Mr. Blum indirectly beneficially owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust, totaling 4,166 indirect shares.

Sentiment

Score: 5

Explanation: The sale of shares by a CEO is generally a neutral to slightly negative signal, but the execution under a Rule 10b5-1 plan mitigates the negative perception, indicating a pre-planned portfolio management activity rather than a reaction to new, negative information.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information.
• Mr. Blum retains a significant beneficial ownership of 402,274 shares (398,108 direct and 4,166 indirect) in Cytokinetics Inc. after the transaction.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing. Such filings are common across all industries for executives managing their personal portfolios, often through pre-arranged plans to avoid accusations of trading on inside information.

Related Party Transactions

• Mr. Blum indirectly holds shares through The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, though the Rule 10b5-1 plan suggests a routine portfolio management decision rather than a lack of confidence.

Key Dates

Recommendation

Keywords

Cytokinetics, CYTK, Robert I. Blum, Insider Sale, Form 4, SEC Filing, Stock Transaction, Rule 10b5-1, CEO, Director, Common Stock